Abstracts

PRENATAL PrEP EXPOSURE AND LONGITUDINAL BIRTH OUTCOMES IN KENYA

PrEP is recommended for use among pregnant and breastfeeding women at risk for acquiring HIV by the World Health Organization and Kenyan Ministry of Health. As PrEP implementation continues, accruing data on birth outcomes following prenatal PrEP exposure remains important. PrEP Implementation for Mothers in Antenatal Care (PrIMA) is a cluster randomized trial in Western…

USING A MOBILE APP AND DRIED BLOT SPOTS TO ASSESS ADHERENCE TO EVENT-DRIVEN PrEP

Both daily and event-driven (i.e. before and after sex) pre-exposure prophylaxis (PrEP) regimens are effective against HIV acquisition. However, information about adherence to event-driven PrEP is scarce and predominantly based on self-reported data collected at 3-month intervals. We used a mobile-based diary application and intracellular tenofovir diphosphate (TFV-DP) levels to assess adherence among event-driven PrEP…

HIV RISK AND OBJECTIVELY MEASURED PrEP ADHERENCE IN YOUNG KENYAN WOMEN

Pre-exposure prophylaxis (PrEP) is a highly effective means for preventing HIV acquisition. However, use among young women has generally been suboptimal and poorly characterized. We present objectively measured adherence and associated socio-behavioral factors among a cohort of young women.  Participants were 18-24 year old women at high risk for HIV in Thika and Kisumu, Kenya.…

USE OF A TENOFOVIR URINE TEST TO IMPROVE PrEP ADHERENCE AND PREDICT NON-RETENTION

Daily pre-exposure prophylaxis (PrEP) effectively prevents new HIV infections. Poor adherence and retention are pervasive, undermining PrEP’s utility. Objective adherence monitoring (OAM) tools that identify non-adherent patients and drive behavioral change are urgently needed. A Liquid Chromatography Mass Spectrometry (LC-MS/MS) urine test for Tenofovir (TFV), a component of PrEP, was used clinically to identify non-adherent…

HIGH PrEP ADHERENCE BASED ON TFV-DP LEVELS IN THAI 15-19-YEAR-OLD MSM AND TRANSWOMEN

Thailand initiated the first regional pre-exposure prophylaxis (PrEP) program in 2014, which has reached 10,000 PrEP users, including adolescents. Our objective was to assess 6-month adherence to oral tenofovir-diphosphate/emtricitabine (TDF/FTC) PrEP among adolescent men who have sex with men (MSM) and transgender women (TGW) in Bangkok. MSM and TGW aged 15-19 years were provided free…

PROPHYLACTIC EFFECT OF PrEP AGAINST HBV INFECTION AMONG MSM

Universal HBV vaccination had not been available in Japan until 2016 and men who have sex with men (MSM) are still vulnerable to hepatitis B virus (HBV) infection. Thus, we evaluated incidence of HBV infection and prophylactic effect of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF/FTC) against HBV infection among a non HIV-infected MSM…